CRL on the way? Aca­dia re­ports a sur­prise hitch in its quest to ex­pand the mar­ket for Nu­plazid — shares rout­ed

A group of en­thu­si­as­tic an­a­lysts cheer­ing on Aca­dia’s share price $ACAD might have to take a knee.

The biotech, which has been whip­ping up en­thu­si­asm on the in­vestor cir­cuit with prospects of ex­pand­ing its fran­chise for Nu­plazid with an OK for de­men­tia-re­lat­ed psy­chosis, an­nounced Mon­day af­ter the mar­ket closed that the FDA had iden­ti­fied un­spec­i­fied “de­fi­cien­cies” in its sN­DA for the drug that for­bade any dis­cus­sions about la­bel­ing and post-mar­ket­ing re­quire­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.